Clinical Trial Update: Study of Reduced-antigen-content Acellular Pertussis Vaccine and Diphtheria-Tetanus-Acellular Pertussis Vaccine [Phase 3]

View source ↗

Summary

Phase 3 trial update of reduced-antigen-content acellular pertussis vaccine and diphtheria-tetanus-acellular pertussis vaccine. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Pertussis
• Tetanus

Drugs mentioned

• Diphtheria-Tetanus-Acellular Pertussis Vaccine (diphtheria-tetanus-acellular pertussis vaccine)
• Reduced-antigen-content acellular pertussis vaccine (reduced-antigen-content acellular pertussis vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Diphteria, Tetanus and Pertussis | Phase 3 | Status: COMPLETED